Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Tuberculosis | 81 | 2024 | 2017 | 8.750 |
Why?
|
Mycobacterium tuberculosis | 84 | 2024 | 1912 | 7.710 |
Why?
|
Tuberculosis, Multidrug-Resistant | 49 | 2024 | 934 | 6.340 |
Why?
|
Tuberculosis, Pulmonary | 30 | 2024 | 830 | 5.280 |
Why?
|
Antitubercular Agents | 51 | 2024 | 1374 | 5.190 |
Why?
|
Peru | 45 | 2024 | 888 | 2.990 |
Why?
|
Isoniazid | 15 | 2024 | 283 | 2.710 |
Why?
|
Contact Tracing | 13 | 2024 | 272 | 2.430 |
Why?
|
Family Characteristics | 17 | 2024 | 992 | 2.420 |
Why?
|
Drug Resistance, Multiple, Bacterial | 13 | 2019 | 585 | 1.610 |
Why?
|
Genome, Bacterial | 10 | 2024 | 785 | 1.510 |
Why?
|
Latent Tuberculosis | 6 | 2024 | 224 | 1.400 |
Why?
|
Vitamin A Deficiency | 2 | 2022 | 88 | 1.370 |
Why?
|
Drug Resistance, Bacterial | 12 | 2019 | 1048 | 1.370 |
Why?
|
Sputum | 13 | 2020 | 505 | 1.320 |
Why?
|
Rifampin | 14 | 2024 | 338 | 1.240 |
Why?
|
Fluoroquinolones | 4 | 2017 | 307 | 1.190 |
Why?
|
Hemorrhagic Fever, Ebola | 6 | 2016 | 419 | 1.080 |
Why?
|
Disease Outbreaks | 13 | 2016 | 1747 | 0.980 |
Why?
|
Microbial Sensitivity Tests | 19 | 2023 | 1936 | 0.860 |
Why?
|
Ebolavirus | 5 | 2016 | 247 | 0.850 |
Why?
|
Rain | 3 | 2017 | 60 | 0.820 |
Why?
|
Pyrazinamide | 5 | 2018 | 60 | 0.810 |
Why?
|
Diabetes Complications | 8 | 2012 | 1316 | 0.770 |
Why?
|
Extensively Drug-Resistant Tuberculosis | 5 | 2024 | 85 | 0.760 |
Why?
|
Vitamin D Deficiency | 2 | 2022 | 1388 | 0.760 |
Why?
|
Models, Theoretical | 12 | 2024 | 3571 | 0.750 |
Why?
|
Communicable Diseases | 4 | 2024 | 873 | 0.730 |
Why?
|
Molecular Epidemiology | 7 | 2015 | 470 | 0.720 |
Why?
|
Disease Transmission, Infectious | 5 | 2021 | 561 | 0.700 |
Why?
|
Rifabutin | 1 | 2019 | 59 | 0.650 |
Why?
|
Yaws | 1 | 2018 | 3 | 0.640 |
Why?
|
Mass Screening | 9 | 2024 | 5426 | 0.620 |
Why?
|
Ethambutol | 3 | 2018 | 59 | 0.600 |
Why?
|
Vitamin E Deficiency | 1 | 2018 | 30 | 0.600 |
Why?
|
Humans | 203 | 2024 | 761222 | 0.600 |
Why?
|
Cluster Analysis | 9 | 2021 | 2706 | 0.590 |
Why?
|
Infectious Disease Incubation Period | 2 | 2015 | 16 | 0.590 |
Why?
|
DNA Gyrase | 2 | 2016 | 85 | 0.580 |
Why?
|
International Cooperation | 4 | 2020 | 1423 | 0.580 |
Why?
|
Radiography, Thoracic | 1 | 2024 | 1302 | 0.580 |
Why?
|
Incidence | 23 | 2020 | 21366 | 0.570 |
Why?
|
Drug Resistance, Microbial | 4 | 2016 | 826 | 0.550 |
Why?
|
Income | 5 | 2023 | 1869 | 0.550 |
Why?
|
Ebola Vaccines | 1 | 2016 | 24 | 0.540 |
Why?
|
Adolescent | 54 | 2024 | 88300 | 0.540 |
Why?
|
Amidohydrolases | 1 | 2016 | 158 | 0.510 |
Why?
|
West Nile Fever | 2 | 2006 | 75 | 0.510 |
Why?
|
Health Services | 2 | 2017 | 750 | 0.510 |
Why?
|
Risk Factors | 40 | 2024 | 74241 | 0.500 |
Why?
|
Poverty | 5 | 2015 | 2691 | 0.500 |
Why?
|
Selection, Genetic | 3 | 2020 | 871 | 0.500 |
Why?
|
Molecular Typing | 2 | 2017 | 116 | 0.490 |
Why?
|
Mutation | 21 | 2024 | 30004 | 0.480 |
Why?
|
Adult | 78 | 2024 | 221120 | 0.470 |
Why?
|
Models, Biological | 8 | 2012 | 9458 | 0.470 |
Why?
|
Child, Preschool | 34 | 2024 | 42225 | 0.460 |
Why?
|
Young Adult | 43 | 2024 | 59222 | 0.460 |
Why?
|
Entamoebiasis | 1 | 2013 | 12 | 0.460 |
Why?
|
Protozoan Infections | 1 | 2013 | 38 | 0.460 |
Why?
|
Amebiasis | 1 | 2013 | 33 | 0.450 |
Why?
|
Social Class | 1 | 2023 | 1993 | 0.450 |
Why?
|
Giardiasis | 1 | 2013 | 28 | 0.450 |
Why?
|
Blastocystis Infections | 1 | 2013 | 17 | 0.450 |
Why?
|
Infant | 28 | 2024 | 36170 | 0.440 |
Why?
|
Ambulatory Care Facilities | 1 | 2020 | 934 | 0.440 |
Why?
|
HIV Infections | 18 | 2020 | 17348 | 0.440 |
Why?
|
Rwanda | 10 | 2024 | 660 | 0.440 |
Why?
|
Socioeconomic Factors | 12 | 2021 | 7804 | 0.440 |
Why?
|
Child | 40 | 2024 | 80154 | 0.440 |
Why?
|
DNA, Bacterial | 8 | 2020 | 1470 | 0.430 |
Why?
|
Qualitative Research | 2 | 2024 | 3024 | 0.430 |
Why?
|
Models, Statistical | 7 | 2016 | 5081 | 0.430 |
Why?
|
Vitamin E | 1 | 2018 | 872 | 0.430 |
Why?
|
Occupational Diseases | 1 | 2021 | 1490 | 0.420 |
Why?
|
Male | 87 | 2024 | 360703 | 0.420 |
Why?
|
Primary Prevention | 1 | 2020 | 1185 | 0.420 |
Why?
|
Host-Pathogen Interactions | 4 | 2024 | 1448 | 0.420 |
Why?
|
Antigens, CD1 | 3 | 2021 | 439 | 0.420 |
Why?
|
Emigration and Immigration | 3 | 2005 | 397 | 0.410 |
Why?
|
Patient Preference | 1 | 2020 | 927 | 0.400 |
Why?
|
Cation Transport Proteins | 2 | 2012 | 324 | 0.400 |
Why?
|
Female | 89 | 2024 | 392552 | 0.400 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2016 | 610 | 0.380 |
Why?
|
Nutritional Status | 2 | 2016 | 1597 | 0.370 |
Why?
|
Middle Aged | 59 | 2024 | 220858 | 0.370 |
Why?
|
AIDS-Related Opportunistic Infections | 4 | 2011 | 662 | 0.360 |
Why?
|
Virus Latency | 2 | 2015 | 354 | 0.360 |
Why?
|
Mining | 1 | 2011 | 93 | 0.350 |
Why?
|
Age Factors | 13 | 2021 | 18384 | 0.340 |
Why?
|
India | 5 | 2015 | 2287 | 0.340 |
Why?
|
BCG Vaccine | 4 | 2018 | 369 | 0.330 |
Why?
|
Prevalence | 20 | 2024 | 15721 | 0.330 |
Why?
|
Public Health | 4 | 2021 | 2672 | 0.320 |
Why?
|
Prospective Studies | 22 | 2024 | 54437 | 0.320 |
Why?
|
Anti-Bacterial Agents | 5 | 2016 | 7407 | 0.320 |
Why?
|
Epidemiologic Methods | 3 | 2014 | 1336 | 0.310 |
Why?
|
Disease Progression | 8 | 2022 | 13511 | 0.310 |
Why?
|
Crime Victims | 1 | 2013 | 347 | 0.310 |
Why?
|
Longitudinal Studies | 7 | 2024 | 14610 | 0.310 |
Why?
|
South Africa | 10 | 2018 | 1843 | 0.310 |
Why?
|
Tuberculosis Vaccines | 1 | 2008 | 48 | 0.310 |
Why?
|
Data Interpretation, Statistical | 3 | 2017 | 2691 | 0.300 |
Why?
|
Ukraine | 2 | 2020 | 149 | 0.300 |
Why?
|
United Nations | 1 | 2008 | 148 | 0.290 |
Why?
|
Opportunistic Infections | 1 | 2010 | 376 | 0.290 |
Why?
|
Survival Analysis | 4 | 2020 | 10088 | 0.290 |
Why?
|
Diabetes Mellitus | 5 | 2012 | 5842 | 0.280 |
Why?
|
Vitamin A | 2 | 2022 | 612 | 0.280 |
Why?
|
Sequence Analysis, DNA | 7 | 2017 | 4739 | 0.280 |
Why?
|
Community-Acquired Infections | 1 | 2011 | 469 | 0.280 |
Why?
|
Gold | 1 | 2011 | 482 | 0.280 |
Why?
|
Infant, Newborn | 16 | 2024 | 26200 | 0.280 |
Why?
|
Polymorphism, Single Nucleotide | 9 | 2024 | 15920 | 0.270 |
Why?
|
Population Surveillance | 4 | 2011 | 2598 | 0.270 |
Why?
|
Taiwan | 3 | 2013 | 522 | 0.260 |
Why?
|
Child Mortality | 3 | 2018 | 199 | 0.260 |
Why?
|
West Nile virus | 1 | 2006 | 77 | 0.260 |
Why?
|
Biodiversity | 1 | 2008 | 345 | 0.260 |
Why?
|
Smoking | 5 | 2021 | 9055 | 0.260 |
Why?
|
Vitamin D | 1 | 2019 | 3301 | 0.250 |
Why?
|
Tobacco Smoke Pollution | 2 | 2013 | 821 | 0.250 |
Why?
|
Environment | 1 | 2011 | 1122 | 0.240 |
Why?
|
Madagascar | 6 | 2021 | 109 | 0.240 |
Why?
|
Quantitative Trait Loci | 2 | 2024 | 2113 | 0.240 |
Why?
|
Air Pollution, Indoor | 3 | 2008 | 900 | 0.240 |
Why?
|
Maternal Health Services | 2 | 2020 | 460 | 0.230 |
Why?
|
Logistic Models | 7 | 2023 | 13249 | 0.230 |
Why?
|
Body Mass Index | 4 | 2017 | 12952 | 0.230 |
Why?
|
Antibiotics, Antitubercular | 4 | 2013 | 99 | 0.230 |
Why?
|
Quality of Health Care | 3 | 2019 | 4321 | 0.230 |
Why?
|
Sierra Leone | 4 | 2016 | 169 | 0.230 |
Why?
|
Bivalvia | 1 | 2023 | 55 | 0.230 |
Why?
|
Guinea Pigs | 2 | 2022 | 1308 | 0.220 |
Why?
|
Lost to Follow-Up | 1 | 2024 | 123 | 0.220 |
Why?
|
Case-Control Studies | 9 | 2021 | 22174 | 0.220 |
Why?
|
National Health Programs | 2 | 2020 | 440 | 0.220 |
Why?
|
Health Facilities | 2 | 2020 | 575 | 0.220 |
Why?
|
Health Status Disparities | 1 | 2015 | 1847 | 0.210 |
Why?
|
Cohort Studies | 18 | 2024 | 41496 | 0.210 |
Why?
|
Tuberculin | 1 | 2022 | 64 | 0.210 |
Why?
|
Alleles | 2 | 2013 | 6857 | 0.210 |
Why?
|
Tuberculin Test | 2 | 2022 | 205 | 0.210 |
Why?
|
Clinical Trials as Topic | 2 | 2016 | 8002 | 0.200 |
Why?
|
Seasons | 3 | 2017 | 1518 | 0.200 |
Why?
|
Rural Population | 7 | 2020 | 2277 | 0.200 |
Why?
|
Evolution, Molecular | 3 | 2013 | 1882 | 0.200 |
Why?
|
Genes, Bacterial | 4 | 2017 | 1073 | 0.200 |
Why?
|
Severe Acute Respiratory Syndrome | 1 | 2003 | 137 | 0.200 |
Why?
|
Indonesia | 4 | 2024 | 128 | 0.200 |
Why?
|
Databases, Genetic | 1 | 2009 | 1741 | 0.200 |
Why?
|
Bacterial Proteins | 7 | 2019 | 3836 | 0.190 |
Why?
|
T-Lymphocytes | 6 | 2021 | 10203 | 0.190 |
Why?
|
Cross-Sectional Studies | 9 | 2024 | 26072 | 0.190 |
Why?
|
Odds Ratio | 6 | 2022 | 9652 | 0.190 |
Why?
|
Communicable Disease Control | 3 | 2021 | 846 | 0.190 |
Why?
|
Anti-HIV Agents | 3 | 2012 | 4527 | 0.190 |
Why?
|
Epidemics | 3 | 2020 | 512 | 0.180 |
Why?
|
CD4 Lymphocyte Count | 5 | 2014 | 2570 | 0.180 |
Why?
|
Aged | 29 | 2024 | 169292 | 0.180 |
Why?
|
Shoes | 1 | 2021 | 92 | 0.180 |
Why?
|
Public Health Practice | 1 | 2003 | 219 | 0.180 |
Why?
|
Cholesterol Ester Transfer Proteins | 1 | 2021 | 113 | 0.180 |
Why?
|
Trehalose | 1 | 2021 | 88 | 0.180 |
Why?
|
Esters | 1 | 2021 | 210 | 0.180 |
Why?
|
Lipids | 5 | 2021 | 3331 | 0.180 |
Why?
|
Treatment Failure | 4 | 2017 | 2643 | 0.180 |
Why?
|
Sulfhydryl Compounds | 1 | 2021 | 296 | 0.170 |
Why?
|
Communicable Diseases, Emerging | 2 | 2013 | 148 | 0.170 |
Why?
|
Probability | 4 | 2011 | 2478 | 0.170 |
Why?
|
Measles Vaccine | 1 | 2000 | 79 | 0.170 |
Why?
|
Treatment Outcome | 16 | 2022 | 64681 | 0.170 |
Why?
|
Glycerol Kinase | 1 | 2019 | 17 | 0.170 |
Why?
|
Genotype | 12 | 2020 | 12985 | 0.170 |
Why?
|
Developing Countries | 6 | 2021 | 2863 | 0.170 |
Why?
|
Time Factors | 14 | 2015 | 39957 | 0.170 |
Why?
|
Multivariate Analysis | 6 | 2017 | 12052 | 0.170 |
Why?
|
World Health Organization | 2 | 2020 | 1321 | 0.170 |
Why?
|
Glycoproteins | 2 | 2018 | 2203 | 0.160 |
Why?
|
Antacids | 1 | 2019 | 94 | 0.160 |
Why?
|
Proportional Hazards Models | 5 | 2020 | 12474 | 0.160 |
Why?
|
Hospital Bed Capacity | 1 | 2020 | 206 | 0.160 |
Why?
|
Papua New Guinea | 1 | 2018 | 46 | 0.160 |
Why?
|
Antigens, CD1d | 1 | 2019 | 228 | 0.160 |
Why?
|
Sex Factors | 5 | 2021 | 10553 | 0.160 |
Why?
|
Amides | 1 | 2021 | 449 | 0.160 |
Why?
|
Focus Groups | 1 | 2024 | 1413 | 0.160 |
Why?
|
Altruism | 1 | 2020 | 208 | 0.160 |
Why?
|
Health Surveys | 5 | 2017 | 4037 | 0.150 |
Why?
|
Genetic Predisposition to Disease | 4 | 2024 | 17897 | 0.150 |
Why?
|
Receptors, Antigen, T-Cell | 4 | 2022 | 2549 | 0.150 |
Why?
|
Immunity, Cellular | 2 | 2017 | 1553 | 0.150 |
Why?
|
Bacterial Typing Techniques | 2 | 2012 | 262 | 0.150 |
Why?
|
Phagosomes | 1 | 2019 | 199 | 0.150 |
Why?
|
Sensitivity and Specificity | 9 | 2020 | 14675 | 0.150 |
Why?
|
Risk Assessment | 6 | 2020 | 24022 | 0.150 |
Why?
|
Capacity Building | 1 | 2020 | 259 | 0.150 |
Why?
|
Measles | 1 | 2000 | 181 | 0.150 |
Why?
|
Macrophages | 4 | 2024 | 5755 | 0.150 |
Why?
|
Mouth Mucosa | 1 | 2020 | 432 | 0.150 |
Why?
|
DNA Fingerprinting | 3 | 2002 | 114 | 0.150 |
Why?
|
Rural Health Services | 2 | 2019 | 384 | 0.150 |
Why?
|
Geologic Sediments | 1 | 2018 | 80 | 0.150 |
Why?
|
Automation | 1 | 2020 | 585 | 0.140 |
Why?
|
Registries | 1 | 2013 | 8246 | 0.140 |
Why?
|
Cough | 1 | 2021 | 594 | 0.140 |
Why?
|
Pulmonary Medicine | 1 | 2019 | 221 | 0.140 |
Why?
|
Cholera | 2 | 2015 | 747 | 0.140 |
Why?
|
Amino Acid Motifs | 1 | 2019 | 924 | 0.140 |
Why?
|
Toilet Facilities | 1 | 2016 | 25 | 0.140 |
Why?
|
Analysis of Variance | 2 | 2020 | 6223 | 0.130 |
Why?
|
Linkage Disequilibrium | 1 | 2021 | 1994 | 0.130 |
Why?
|
Fees and Charges | 1 | 2017 | 192 | 0.130 |
Why?
|
Medication Adherence | 3 | 2014 | 2175 | 0.130 |
Why?
|
HIV | 3 | 2015 | 1581 | 0.130 |
Why?
|
Health Policy | 4 | 2024 | 2679 | 0.130 |
Why?
|
Receptors, Antigen, T-Cell, alpha-beta | 1 | 2019 | 800 | 0.130 |
Why?
|
Nucleoproteins | 1 | 2016 | 110 | 0.130 |
Why?
|
Phylogeny | 5 | 2016 | 2809 | 0.130 |
Why?
|
Demography | 2 | 2017 | 1641 | 0.130 |
Why?
|
Mycolic Acids | 2 | 2020 | 54 | 0.130 |
Why?
|
Lab-On-A-Chip Devices | 1 | 2020 | 432 | 0.130 |
Why?
|
Data Collection | 4 | 2018 | 3320 | 0.130 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2011 | 12159 | 0.130 |
Why?
|
Educational Status | 1 | 2023 | 2510 | 0.120 |
Why?
|
Pandemics | 5 | 2024 | 8663 | 0.120 |
Why?
|
Diarrhea | 3 | 2017 | 1316 | 0.120 |
Why?
|
Feces | 2 | 2019 | 1490 | 0.120 |
Why?
|
Chi-Square Distribution | 2 | 2011 | 3418 | 0.120 |
Why?
|
Th17 Cells | 1 | 2021 | 794 | 0.120 |
Why?
|
Antiretroviral Therapy, Highly Active | 2 | 2014 | 1895 | 0.120 |
Why?
|
Child Development | 3 | 2018 | 2302 | 0.120 |
Why?
|
Ofloxacin | 2 | 2011 | 66 | 0.120 |
Why?
|
Aged, 80 and over | 12 | 2021 | 58952 | 0.120 |
Why?
|
Radiography | 2 | 2022 | 6974 | 0.120 |
Why?
|
Entamoeba | 1 | 2013 | 5 | 0.120 |
Why?
|
Endolimax | 1 | 2013 | 6 | 0.120 |
Why?
|
Blastocystis hominis | 1 | 2013 | 6 | 0.120 |
Why?
|
Immunologic Memory | 1 | 2021 | 1361 | 0.120 |
Why?
|
Guideline Adherence | 1 | 2024 | 2220 | 0.120 |
Why?
|
Carotenoids | 1 | 2017 | 621 | 0.120 |
Why?
|
Anticholesteremic Agents | 1 | 2021 | 968 | 0.120 |
Why?
|
Anti-Retroviral Agents | 2 | 2017 | 1784 | 0.110 |
Why?
|
Giardia lamblia | 1 | 2013 | 23 | 0.110 |
Why?
|
Health Services Needs and Demand | 2 | 2020 | 1401 | 0.110 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2015 | 239 | 0.110 |
Why?
|
Child Health Services | 1 | 2019 | 644 | 0.110 |
Why?
|
Body Height | 1 | 2020 | 1566 | 0.110 |
Why?
|
Infant Mortality | 1 | 2018 | 752 | 0.110 |
Why?
|
Retrospective Studies | 14 | 2018 | 80675 | 0.110 |
Why?
|
Autoantigens | 1 | 2018 | 888 | 0.110 |
Why?
|
Epidemiologic Research Design | 2 | 2021 | 368 | 0.110 |
Why?
|
Biological Assay | 1 | 2016 | 623 | 0.110 |
Why?
|
Specimen Handling | 1 | 2018 | 702 | 0.110 |
Why?
|
Economic Development | 1 | 2014 | 69 | 0.110 |
Why?
|
Point-of-Care Systems | 3 | 2020 | 1212 | 0.110 |
Why?
|
Cost of Illness | 3 | 2010 | 1936 | 0.110 |
Why?
|
Cause of Death | 2 | 2018 | 3688 | 0.110 |
Why?
|
Dendritic Cells | 1 | 2024 | 2726 | 0.110 |
Why?
|
Community Health Planning | 1 | 2013 | 164 | 0.110 |
Why?
|
Sentinel Surveillance | 2 | 2021 | 291 | 0.110 |
Why?
|
Genetic Loci | 2 | 2019 | 2623 | 0.110 |
Why?
|
Metformin | 1 | 2020 | 910 | 0.100 |
Why?
|
Insurance, Health | 2 | 2017 | 2493 | 0.100 |
Why?
|
RNA, Viral | 3 | 2016 | 2839 | 0.100 |
Why?
|
Disease Susceptibility | 3 | 2007 | 1791 | 0.100 |
Why?
|
Species Specificity | 2 | 2008 | 2406 | 0.100 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3093 | 0.100 |
Why?
|
Alcohol Drinking | 2 | 2016 | 4027 | 0.100 |
Why?
|
Aminoglycosides | 1 | 2013 | 160 | 0.100 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3215 | 0.100 |
Why?
|
Cholera Vaccines | 1 | 2015 | 262 | 0.100 |
Why?
|
DNA Mutational Analysis | 2 | 2019 | 4107 | 0.100 |
Why?
|
Overweight | 1 | 2023 | 2418 | 0.100 |
Why?
|
Population Dynamics | 1 | 2014 | 308 | 0.100 |
Why?
|
Urban Population | 2 | 2017 | 2036 | 0.100 |
Why?
|
5' Untranslated Regions | 1 | 2013 | 251 | 0.100 |
Why?
|
Community Networks | 1 | 2013 | 202 | 0.090 |
Why?
|
Mortality | 2 | 2021 | 2896 | 0.090 |
Why?
|
Quality Improvement | 2 | 2019 | 3808 | 0.090 |
Why?
|
Forecasting | 2 | 2020 | 2928 | 0.090 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2016 | 4567 | 0.090 |
Why?
|
Antigens, Viral | 1 | 2015 | 989 | 0.090 |
Why?
|
Catalase | 1 | 2011 | 217 | 0.090 |
Why?
|
Binding Sites | 1 | 2019 | 5988 | 0.090 |
Why?
|
Mutation, Missense | 1 | 2020 | 2567 | 0.090 |
Why?
|
Comorbidity | 4 | 2014 | 10516 | 0.090 |
Why?
|
Gene Duplication | 1 | 2012 | 314 | 0.090 |
Why?
|
Models, Econometric | 2 | 2014 | 215 | 0.090 |
Why?
|
Growth Disorders | 1 | 2015 | 634 | 0.090 |
Why?
|
Genetic Variation | 5 | 2024 | 6567 | 0.090 |
Why?
|
Biomedical Research | 2 | 2018 | 3434 | 0.090 |
Why?
|
Water | 1 | 2016 | 1410 | 0.090 |
Why?
|
Empirical Research | 1 | 2010 | 120 | 0.090 |
Why?
|
Premature Birth | 1 | 2022 | 1784 | 0.090 |
Why?
|
Autoimmunity | 1 | 2018 | 1356 | 0.090 |
Why?
|
Smoking Cessation | 1 | 2021 | 2056 | 0.080 |
Why?
|
Principal Component Analysis | 1 | 2012 | 942 | 0.080 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2018 | 3777 | 0.080 |
Why?
|
Cost-Benefit Analysis | 5 | 2014 | 5493 | 0.080 |
Why?
|
Gene Expression Regulation, Bacterial | 2 | 2019 | 1131 | 0.080 |
Why?
|
Promoter Regions, Genetic | 2 | 2019 | 5773 | 0.080 |
Why?
|
Program Evaluation | 1 | 2017 | 2489 | 0.080 |
Why?
|
Basic Reproduction Number | 1 | 2008 | 36 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 1 | 2019 | 6486 | 0.080 |
Why?
|
Social Environment | 1 | 2014 | 1022 | 0.080 |
Why?
|
Malnutrition | 1 | 2015 | 622 | 0.080 |
Why?
|
Reproducibility of Results | 7 | 2017 | 20118 | 0.080 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2020 | 2150 | 0.080 |
Why?
|
Biological Evolution | 2 | 2021 | 1075 | 0.080 |
Why?
|
Vaccination | 2 | 2024 | 3369 | 0.080 |
Why?
|
Africa South of the Sahara | 2 | 2012 | 745 | 0.070 |
Why?
|
Computer Simulation | 6 | 2013 | 6224 | 0.070 |
Why?
|
Feeding Behavior | 2 | 2017 | 3183 | 0.070 |
Why?
|
Delivery of Health Care | 3 | 2021 | 5333 | 0.070 |
Why?
|
Hypoglycemic Agents | 1 | 2020 | 3089 | 0.070 |
Why?
|
Gene Expression | 2 | 2019 | 7571 | 0.070 |
Why?
|
Interviews as Topic | 3 | 2024 | 2697 | 0.070 |
Why?
|
Research Design | 2 | 2010 | 6180 | 0.070 |
Why?
|
Critical Care | 1 | 2020 | 2696 | 0.070 |
Why?
|
Survival Rate | 2 | 2015 | 12728 | 0.070 |
Why?
|
Microscopy, Fluorescence | 1 | 2014 | 2635 | 0.070 |
Why?
|
Infection Control | 3 | 2020 | 983 | 0.070 |
Why?
|
Clinical Laboratory Techniques | 1 | 2012 | 746 | 0.070 |
Why?
|
Critical Illness | 1 | 2020 | 2724 | 0.070 |
Why?
|
Mycobacterium | 1 | 2008 | 251 | 0.070 |
Why?
|
Netherlands | 2 | 2002 | 2222 | 0.070 |
Why?
|
Macrophages, Alveolar | 1 | 2009 | 410 | 0.070 |
Why?
|
Siberia | 1 | 2006 | 30 | 0.070 |
Why?
|
Financial Management | 1 | 2008 | 160 | 0.070 |
Why?
|
Bayes Theorem | 2 | 2012 | 2329 | 0.070 |
Why?
|
Information Centers | 1 | 2006 | 2 | 0.070 |
Why?
|
Oseltamivir | 1 | 2007 | 75 | 0.070 |
Why?
|
Follow-Up Studies | 5 | 2021 | 39127 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2021 | 10218 | 0.070 |
Why?
|
Nonlinear Dynamics | 1 | 2008 | 492 | 0.070 |
Why?
|
Drug Administration Schedule | 2 | 2011 | 4851 | 0.060 |
Why?
|
Genome-Wide Association Study | 3 | 2020 | 12676 | 0.060 |
Why?
|
Drug Therapy, Combination | 2 | 2019 | 6304 | 0.060 |
Why?
|
Food Supply | 1 | 2011 | 539 | 0.060 |
Why?
|
Resource Allocation | 1 | 2008 | 350 | 0.060 |
Why?
|
Orthomyxoviridae | 1 | 2007 | 149 | 0.060 |
Why?
|
Risk | 2 | 2017 | 9616 | 0.060 |
Why?
|
Antibodies, Viral | 1 | 2016 | 3149 | 0.060 |
Why?
|
Gene Expression Profiling | 3 | 2024 | 9417 | 0.060 |
Why?
|
Malaria | 1 | 2015 | 1225 | 0.060 |
Why?
|
Immunophenotyping | 2 | 2020 | 1867 | 0.060 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2013 | 940 | 0.060 |
Why?
|
Treatment Refusal | 1 | 2008 | 430 | 0.060 |
Why?
|
Thioredoxin-Disulfide Reductase | 1 | 2024 | 52 | 0.060 |
Why?
|
Self Report | 2 | 2015 | 3727 | 0.060 |
Why?
|
Phenotype | 5 | 2021 | 16575 | 0.060 |
Why?
|
Disclosure | 1 | 2010 | 747 | 0.060 |
Why?
|
HIV Seropositivity | 1 | 2010 | 957 | 0.060 |
Why?
|
Animals | 9 | 2023 | 168089 | 0.060 |
Why?
|
Regression Analysis | 2 | 2011 | 6345 | 0.060 |
Why?
|
Escherichia coli O157 | 1 | 2004 | 53 | 0.060 |
Why?
|
Missouri | 1 | 2024 | 115 | 0.060 |
Why?
|
DNA Repair | 1 | 2013 | 2041 | 0.060 |
Why?
|
Private Practice | 1 | 2024 | 152 | 0.060 |
Why?
|
Peroxidases | 1 | 2004 | 134 | 0.060 |
Why?
|
Kenya | 2 | 2024 | 756 | 0.060 |
Why?
|
Blood Donors | 1 | 2006 | 345 | 0.060 |
Why?
|
Health Status | 1 | 2017 | 4077 | 0.050 |
Why?
|
Geographic Information Systems | 2 | 2018 | 281 | 0.050 |
Why?
|
Environment, Controlled | 1 | 2003 | 42 | 0.050 |
Why?
|
Antigen Presentation | 2 | 2019 | 1251 | 0.050 |
Why?
|
Virulence | 2 | 2004 | 1296 | 0.050 |
Why?
|
Hong Kong | 1 | 2003 | 164 | 0.050 |
Why?
|
Causality | 1 | 2009 | 1244 | 0.050 |
Why?
|
Public Health Administration | 1 | 2005 | 242 | 0.050 |
Why?
|
Algeria | 1 | 2002 | 5 | 0.050 |
Why?
|
Ambulatory Care | 1 | 2013 | 2770 | 0.050 |
Why?
|
Patient Isolation | 1 | 2003 | 100 | 0.050 |
Why?
|
Health Services Research | 1 | 2010 | 1807 | 0.050 |
Why?
|
Genetic Association Studies | 1 | 2012 | 2731 | 0.050 |
Why?
|
Singapore | 1 | 2003 | 292 | 0.050 |
Why?
|
Air Microbiology | 1 | 2003 | 95 | 0.050 |
Why?
|
Internet | 2 | 2012 | 3096 | 0.050 |
Why?
|
Quality-Adjusted Life Years | 2 | 2006 | 1723 | 0.050 |
Why?
|
Thailand | 1 | 2023 | 287 | 0.050 |
Why?
|
Sudan | 1 | 2002 | 86 | 0.050 |
Why?
|
Bioterrorism | 1 | 2003 | 144 | 0.050 |
Why?
|
Age Distribution | 2 | 2021 | 2871 | 0.050 |
Why?
|
Models, Economic | 1 | 2006 | 714 | 0.050 |
Why?
|
Health Services Accessibility | 2 | 2017 | 5426 | 0.050 |
Why?
|
Mathematics | 1 | 2003 | 702 | 0.050 |
Why?
|
Endemic Diseases | 1 | 2003 | 191 | 0.050 |
Why?
|
Africa | 1 | 2024 | 714 | 0.050 |
Why?
|
Stochastic Processes | 1 | 2003 | 355 | 0.050 |
Why?
|
Depressive Disorder | 1 | 2014 | 3727 | 0.050 |
Why?
|
Drug Resistance, Viral | 1 | 2007 | 862 | 0.050 |
Why?
|
Haiti | 2 | 2015 | 549 | 0.050 |
Why?
|
Disease Management | 1 | 2012 | 2507 | 0.050 |
Why?
|
Program Development | 3 | 2013 | 1294 | 0.050 |
Why?
|
Oxidoreductases | 1 | 2004 | 411 | 0.050 |
Why?
|
Health Care Costs | 2 | 2012 | 3239 | 0.050 |
Why?
|
Community Health Centers | 1 | 2005 | 461 | 0.050 |
Why?
|
Sequence Homology, Nucleic Acid | 1 | 2002 | 1053 | 0.050 |
Why?
|
United States | 7 | 2020 | 72341 | 0.050 |
Why?
|
Autopsy | 2 | 2018 | 1010 | 0.050 |
Why?
|
Models, Genetic | 1 | 2011 | 3430 | 0.050 |
Why?
|
Liberia | 1 | 2021 | 174 | 0.050 |
Why?
|
Drug Discovery | 1 | 2009 | 1048 | 0.050 |
Why?
|
Minor Histocompatibility Antigens | 1 | 2022 | 294 | 0.050 |
Why?
|
Quarantine | 1 | 2003 | 182 | 0.050 |
Why?
|
Prisons | 1 | 2023 | 174 | 0.050 |
Why?
|
Obesity | 1 | 2023 | 12940 | 0.050 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2012 | 4340 | 0.040 |
Why?
|
Microfibrils | 1 | 2020 | 16 | 0.040 |
Why?
|
Indians, South American | 1 | 2020 | 34 | 0.040 |
Why?
|
Immunocompromised Host | 1 | 2006 | 858 | 0.040 |
Why?
|
Europe | 1 | 2007 | 3423 | 0.040 |
Why?
|
Biological Specimen Banks | 1 | 2006 | 780 | 0.040 |
Why?
|
Hospitals | 2 | 2010 | 3881 | 0.040 |
Why?
|
Molluscum Contagiosum | 1 | 1980 | 15 | 0.040 |
Why?
|
Selection Bias | 1 | 2002 | 359 | 0.040 |
Why?
|
Patient Acceptance of Health Care | 3 | 2019 | 3200 | 0.040 |
Why?
|
Gene Expression Regulation | 4 | 2024 | 11855 | 0.040 |
Why?
|
Mycobacterium kansasii | 1 | 2019 | 8 | 0.040 |
Why?
|
Seroepidemiologic Studies | 1 | 2021 | 399 | 0.040 |
Why?
|
Heredity | 1 | 2020 | 148 | 0.040 |
Why?
|
Neuropsychological Tests | 1 | 2012 | 7046 | 0.040 |
Why?
|
Streptomycin | 2 | 2011 | 69 | 0.040 |
Why?
|
Superoxides | 1 | 2020 | 388 | 0.040 |
Why?
|
Membrane Potential, Mitochondrial | 1 | 2020 | 295 | 0.040 |
Why?
|
China | 2 | 2020 | 2374 | 0.040 |
Why?
|
Pakistan | 1 | 2000 | 292 | 0.040 |
Why?
|
Regional Medical Programs | 1 | 2019 | 66 | 0.040 |
Why?
|
Immunosuppressive Agents | 1 | 2012 | 4190 | 0.040 |
Why?
|
Glycolipids | 1 | 2020 | 206 | 0.040 |
Why?
|
Malawi | 1 | 2020 | 300 | 0.040 |
Why?
|
Uganda | 1 | 2024 | 1332 | 0.040 |
Why?
|
Blood Transfusion | 1 | 2006 | 1303 | 0.040 |
Why?
|
Tanzania | 2 | 2014 | 1390 | 0.040 |
Why?
|
Immunization Schedule | 1 | 2000 | 227 | 0.040 |
Why?
|
Mucous Membrane | 1 | 2022 | 659 | 0.040 |
Why?
|
Hospitalization | 2 | 2020 | 10707 | 0.040 |
Why?
|
Nitroimidazoles | 1 | 2019 | 117 | 0.040 |
Why?
|
Prisoners | 1 | 2002 | 314 | 0.040 |
Why?
|
RNA, Bacterial | 1 | 2020 | 393 | 0.040 |
Why?
|
Genes, MDR | 1 | 2018 | 36 | 0.040 |
Why?
|
Oxazoles | 1 | 2019 | 199 | 0.040 |
Why?
|
Sex Distribution | 2 | 2014 | 2277 | 0.040 |
Why?
|
Automation, Laboratory | 1 | 2018 | 102 | 0.040 |
Why?
|
Ultraviolet Rays | 1 | 2003 | 1078 | 0.040 |
Why?
|
Directly Observed Therapy | 2 | 2010 | 139 | 0.040 |
Why?
|
Severity of Illness Index | 2 | 2014 | 15841 | 0.040 |
Why?
|
Lectins, C-Type | 1 | 2021 | 585 | 0.040 |
Why?
|
Cities | 1 | 2020 | 541 | 0.040 |
Why?
|
Antigen-Presenting Cells | 1 | 2021 | 965 | 0.040 |
Why?
|
Sampling Studies | 1 | 2018 | 615 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2009 | 10756 | 0.030 |
Why?
|
Canada | 1 | 2002 | 2125 | 0.030 |
Why?
|
Algorithms | 3 | 2014 | 14025 | 0.030 |
Why?
|
Sodium-Potassium-Exchanging ATPase | 1 | 2019 | 476 | 0.030 |
Why?
|
Monte Carlo Method | 1 | 2002 | 1256 | 0.030 |
Why?
|
Polymerase Chain Reaction | 3 | 2013 | 6067 | 0.030 |
Why?
|
Glucose Intolerance | 1 | 2020 | 575 | 0.030 |
Why?
|
Herpes Simplex | 1 | 1980 | 465 | 0.030 |
Why?
|
Carrier Proteins | 1 | 2009 | 4935 | 0.030 |
Why?
|
Conserved Sequence | 1 | 2019 | 1162 | 0.030 |
Why?
|
HIV-1 | 1 | 2013 | 6851 | 0.030 |
Why?
|
Sanitation | 1 | 2016 | 82 | 0.030 |
Why?
|
Cardiovascular Diseases | 1 | 2022 | 15521 | 0.030 |
Why?
|
Area Under Curve | 1 | 2020 | 1636 | 0.030 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2019 | 822 | 0.030 |
Why?
|
Nucleic Acid Amplification Techniques | 1 | 2018 | 330 | 0.030 |
Why?
|
Organizations | 1 | 2016 | 172 | 0.030 |
Why?
|
Base Sequence | 2 | 2006 | 12404 | 0.030 |
Why?
|
Influenza, Human | 1 | 2007 | 1521 | 0.030 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2022 | 1348 | 0.030 |
Why?
|
Electronic Health Records | 1 | 2012 | 4822 | 0.030 |
Why?
|
Molecular Structure | 1 | 2019 | 1875 | 0.030 |
Why?
|
Pregnancy | 3 | 2022 | 29893 | 0.030 |
Why?
|
Databases, Factual | 2 | 2011 | 7965 | 0.030 |
Why?
|
Lung | 3 | 2020 | 9979 | 0.030 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2019 | 2478 | 0.030 |
Why?
|
Protein Multimerization | 1 | 2019 | 974 | 0.030 |
Why?
|
Gene Rearrangement | 1 | 2019 | 1125 | 0.030 |
Why?
|
Vaccines, Inactivated | 1 | 2015 | 178 | 0.030 |
Why?
|
Antiviral Agents | 1 | 2007 | 3048 | 0.030 |
Why?
|
Health Expenditures | 2 | 2020 | 2362 | 0.030 |
Why?
|
Structure-Activity Relationship | 1 | 2019 | 3057 | 0.030 |
Why?
|
Mali | 1 | 2013 | 50 | 0.030 |
Why?
|
DNA Transposable Elements | 2 | 2011 | 754 | 0.030 |
Why?
|
Maternal Mortality | 1 | 2017 | 301 | 0.030 |
Why?
|
Lysosomes | 1 | 2019 | 921 | 0.030 |
Why?
|
Anthropometry | 1 | 2018 | 1338 | 0.030 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2008 | 3201 | 0.030 |
Why?
|
Genetic Speciation | 1 | 2013 | 38 | 0.030 |
Why?
|
Social Support | 2 | 2014 | 2175 | 0.030 |
Why?
|
Marital Status | 1 | 2014 | 425 | 0.030 |
Why?
|
Gene Frequency | 1 | 2020 | 3603 | 0.030 |
Why?
|
Africa, Southern | 1 | 2012 | 60 | 0.030 |
Why?
|
Quality of Life | 1 | 2014 | 13367 | 0.030 |
Why?
|
San Francisco | 1 | 2013 | 162 | 0.030 |
Why?
|
Residence Characteristics | 1 | 2002 | 2092 | 0.030 |
Why?
|
Biomarkers, Pharmacological | 1 | 2013 | 161 | 0.030 |
Why?
|
Government Programs | 1 | 2014 | 278 | 0.030 |
Why?
|
Interferon-gamma | 1 | 2021 | 3155 | 0.030 |
Why?
|
ROC Curve | 1 | 2020 | 3584 | 0.030 |
Why?
|
Health Care Surveys | 1 | 2019 | 2425 | 0.020 |
Why?
|
Chile | 1 | 2012 | 256 | 0.020 |
Why?
|
Protein Conformation | 1 | 2019 | 3933 | 0.020 |
Why?
|
Patient Compliance | 2 | 2012 | 2688 | 0.020 |
Why?
|
Conservation of Natural Resources | 1 | 2014 | 208 | 0.020 |
Why?
|
Immunoassay | 1 | 2015 | 743 | 0.020 |
Why?
|
Reserpine | 1 | 2011 | 63 | 0.020 |
Why?
|
Microfluidic Analytical Techniques | 1 | 2018 | 799 | 0.020 |
Why?
|
Pregnancy Outcome | 1 | 2022 | 2923 | 0.020 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 1 | 2014 | 250 | 0.020 |
Why?
|
Computer Systems | 1 | 2012 | 470 | 0.020 |
Why?
|
Genetic Markers | 1 | 2017 | 2599 | 0.020 |
Why?
|
Therapeutic Equipoise | 1 | 2010 | 29 | 0.020 |
Why?
|
Bacteriological Techniques | 1 | 2012 | 275 | 0.020 |
Why?
|
Verapamil | 1 | 2011 | 242 | 0.020 |
Why?
|
Spectrometry, Mass, Electrospray Ionization | 1 | 2011 | 265 | 0.020 |
Why?
|
Family | 1 | 2021 | 3192 | 0.020 |
Why?
|
Information Systems | 1 | 2012 | 396 | 0.020 |
Why?
|
Immune Reconstitution Inflammatory Syndrome | 1 | 2010 | 61 | 0.020 |
Why?
|
Decision Making | 1 | 2024 | 3931 | 0.020 |
Why?
|
Monocytes | 1 | 2019 | 2570 | 0.020 |
Why?
|
Adrenergic Uptake Inhibitors | 1 | 2011 | 186 | 0.020 |
Why?
|
Molecular Sequence Data | 1 | 2002 | 17598 | 0.020 |
Why?
|
Single-Cell Analysis | 1 | 2021 | 2452 | 0.020 |
Why?
|
Financing, Personal | 1 | 2012 | 308 | 0.020 |
Why?
|
Patient Dropouts | 1 | 2012 | 411 | 0.020 |
Why?
|
Immunoblotting | 1 | 2013 | 1644 | 0.020 |
Why?
|
Child Welfare | 1 | 2013 | 521 | 0.020 |
Why?
|
Models, Molecular | 1 | 2019 | 5406 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 3803 | 0.020 |
Why?
|
Viral Proteins | 1 | 2016 | 1798 | 0.020 |
Why?
|
Quality Indicators, Health Care | 1 | 2019 | 1789 | 0.020 |
Why?
|
Energy Metabolism | 1 | 2020 | 2877 | 0.020 |
Why?
|
Republic of Korea | 1 | 2011 | 576 | 0.020 |
Why?
|
Epidemiologic Studies | 1 | 2012 | 677 | 0.020 |
Why?
|
Mice | 5 | 2019 | 81330 | 0.020 |
Why?
|
Observer Variation | 1 | 2015 | 2610 | 0.020 |
Why?
|
Recurrence | 2 | 2012 | 8457 | 0.020 |
Why?
|
Respiratory Tract Infections | 1 | 2017 | 1009 | 0.020 |
Why?
|
DNA-Directed RNA Polymerases | 1 | 2011 | 366 | 0.020 |
Why?
|
Vibrio cholerae | 1 | 2015 | 791 | 0.020 |
Why?
|
Lipocalins | 1 | 2009 | 161 | 0.020 |
Why?
|
Glucose | 1 | 2020 | 4342 | 0.020 |
Why?
|
Inpatients | 1 | 2020 | 2545 | 0.020 |
Why?
|
Periodicals as Topic | 1 | 2019 | 1463 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2018 | 2756 | 0.020 |
Why?
|
Social Stigma | 1 | 2014 | 770 | 0.020 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2011 | 1535 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2021 | 3608 | 0.020 |
Why?
|
Calcium Channel Blockers | 1 | 2011 | 691 | 0.020 |
Why?
|
Nitric Oxide Synthase | 1 | 2010 | 909 | 0.020 |
Why?
|
Practice Guidelines as Topic | 1 | 2024 | 7400 | 0.020 |
Why?
|
Protein Binding | 1 | 2019 | 9297 | 0.020 |
Why?
|
Societies, Medical | 1 | 2019 | 3923 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2019 | 3634 | 0.020 |
Why?
|
Microscopy | 1 | 2012 | 904 | 0.020 |
Why?
|
Lymphocyte Activation | 1 | 2018 | 5478 | 0.020 |
Why?
|
Planning Techniques | 1 | 2007 | 82 | 0.020 |
Why?
|
Administration, Oral | 1 | 2015 | 4015 | 0.020 |
Why?
|
Body Weight | 1 | 2017 | 4618 | 0.020 |
Why?
|
Intensive Care Units | 1 | 2020 | 3744 | 0.020 |
Why?
|
Insulin Resistance | 1 | 2020 | 3952 | 0.020 |
Why?
|
Prognosis | 2 | 2020 | 29688 | 0.020 |
Why?
|
Secondary Prevention | 1 | 2012 | 1472 | 0.020 |
Why?
|
Value of Life | 1 | 2006 | 98 | 0.020 |
Why?
|
DNA, Intergenic | 1 | 2006 | 105 | 0.020 |
Why?
|
Cell Line | 2 | 2010 | 15545 | 0.020 |
Why?
|
Checklist | 1 | 2012 | 828 | 0.020 |
Why?
|
Cytokines | 1 | 2020 | 7386 | 0.020 |
Why?
|
Caregivers | 1 | 2017 | 2244 | 0.020 |
Why?
|
Education | 1 | 2008 | 536 | 0.020 |
Why?
|
Metabolic Networks and Pathways | 1 | 2009 | 790 | 0.020 |
Why?
|
Emergency Medical Services | 1 | 2016 | 1920 | 0.010 |
Why?
|
Emigrants and Immigrants | 1 | 2011 | 544 | 0.010 |
Why?
|
Computational Biology | 2 | 2009 | 3499 | 0.010 |
Why?
|
Budgets | 1 | 2006 | 230 | 0.010 |
Why?
|
Electrophoresis, Gel, Pulsed-Field | 1 | 2004 | 141 | 0.010 |
Why?
|
Cooperative Behavior | 1 | 2011 | 1506 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 2008 | 13386 | 0.010 |
Why?
|
Developmental Disabilities | 1 | 2012 | 1510 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2020 | 6586 | 0.010 |
Why?
|
Cell Culture Techniques | 1 | 2011 | 1662 | 0.010 |
Why?
|
Meta-Analysis as Topic | 1 | 2008 | 1381 | 0.010 |
Why?
|
Open Reading Frames | 1 | 2006 | 811 | 0.010 |
Why?
|
Blotting, Western | 1 | 2010 | 5032 | 0.010 |
Why?
|
Health Personnel | 1 | 2016 | 3337 | 0.010 |
Why?
|
Colony Count, Microbial | 1 | 2003 | 328 | 0.010 |
Why?
|
Ventilation | 1 | 2003 | 128 | 0.010 |
Why?
|
Filtration | 1 | 2003 | 228 | 0.010 |
Why?
|
Mice, Inbred BALB C | 1 | 2011 | 6200 | 0.010 |
Why?
|
NF-kappa B | 1 | 2010 | 2475 | 0.010 |
Why?
|
DNA Primers | 1 | 2006 | 2814 | 0.010 |
Why?
|
Nitric Oxide | 1 | 2010 | 2137 | 0.010 |
Why?
|
Fatty Acids | 1 | 2009 | 1807 | 0.010 |
Why?
|
Evaluation Studies as Topic | 1 | 2003 | 1624 | 0.010 |
Why?
|
Diet | 1 | 2017 | 8048 | 0.010 |
Why?
|
Starvation | 1 | 1980 | 141 | 0.010 |
Why?
|
Gene Deletion | 1 | 2006 | 2658 | 0.010 |
Why?
|
Drug Costs | 1 | 2006 | 1183 | 0.010 |
Why?
|
Cognition | 1 | 2015 | 6988 | 0.010 |
Why?
|
Software | 1 | 2009 | 4431 | 0.010 |
Why?
|
Food | 1 | 1980 | 768 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2009 | 10423 | 0.010 |
Why?
|
Polymorphism, Genetic | 1 | 2003 | 4243 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2011 | 18222 | 0.010 |
Why?
|
Substance-Related Disorders | 1 | 2008 | 4413 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2009 | 22128 | 0.010 |
Why?
|
Mental Disorders | 1 | 2008 | 6823 | 0.000 |
Why?
|